

June 23, 2020

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA	To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804
--	--

Dear Sir,

Sub: Submission of copies of notices published in Newspapers.

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we herewith enclose notice for the attention of equity shareholders of the Company published on 23.06.2020, intimating that the equity shares in respect of which dividend remain unclaimed for seven consecutive years, would be transferred to Investor Education and Protection Fund (IEPF), in the following newspapers.

- Business Standard (English daily)
- Andhra Prabha (Telugu daily).

Kindly take the above information on record.

Yours faithfully,

For AUROBINDO PHARMA LIMITED


B. Adi Reddy
Company Secretary



AUROBINDO PHARMA LIMITED

(CIN : L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad - 500 084 T.S., INDIA Tel : +91 40 6672 5000 / 1200 Fax : +91 40 6707 4059

Regd. Off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038. T.S., INDIA Tel : +91 40 2373 6370 Fax : +91 40 2374 7340, Email : info@aurobindo.com

www.aurobindo.com

Cadila-CSIR's sepsis drug shows promise in fight against Covid-19

The drug is all set to go to phase 3 of clinical trials after the earlier phase showed positive results

SOHINI DAS
Mumbai, 22 June

As the race to find treatment or vaccine for Covid-19 heats up, Ahmedabad-based Cadila Pharmaceuticals and the Council of Scientific and Industrial Research's (CSIR's) Sepsivac is all set to enter Phase 3 clinical trials after the earlier phase showed positive results. The public-private partnership trial-generated data will be soon presented before the country's drug regulator to see if it can get emergency-use authorisation. "By July 15, we will have the necessary data from the Phase 2 trials and again approach the regulator to see if this drug can be given emergency-use authorisation in the wake of the pandemic. Meanwhile, we also have the approval in place to start two Phase 3 trials — one on 600 patients, another on 500 patients — for this drug," said Ram A Vishwakarma, director, CSIR-Indian Institute of Integrative Medicine.

The Phase 2 trials were conducted across Postgraduate Institute of Medical Education and Research, Chandigarh, All India Institute of Medical Sciences (AIIMS) Delhi, and AIIMS, Bhopal. For the third phase, two more sites will be added — AIIMS

WHAT IS SEPSIVAC

- Sepsivac is used to treat sepsis, a life-threatening infection
- It has a two-pronged approach — boosts innate immunity & inhibits inflammatory response of body
- Humans have innate and acquired immunity. Sepsivac kickstarts the innate immunity in a person
- Acquired immunity or conventional vaccines work via antibodies
- Sepsivac is different from a conventional vaccine
- It inhibits IL6 or inflammatory cytokines that attack the organs
- If organ damage is controlled, body's innate immunity then helps fight the virus



Raipur and a Banaras Hindu University institute. Sepsivac is an immunomodulator drug. Researchers feel the drug works in a two-pronged approach. One, it kick-starts the innate immunity system to act against the pathogen. Two, it also works to reduce the release of inflammatory Cytokine IL-6 that

attacks internal organs. Vishwakarma explained that Sepsivac is not an antibody-generating vaccine. "It can be called a therapeutic vaccine that will kick-start the innate immunity. There are two kinds of immunity in our body — innate immunity that we are born with and get from our ancestors and there is the

acquired immunity. Acquired immunity is mostly governed by antibodies," said Vishwakarma. Whenever a virus or bacteria attacks our body, the innate immunity or trained immunity first reacts. "We are boosting this trained immunity or what we call scientifically, Th1 (T helper type 1). It reacts in most patients, which is why they get cured. In some with comorbidities, their immune system is already compromised," said Vishwakarma. Given in the early phase of infection, it protects the patient from infection. The second way in which this drug works is by inhibiting the IL-6 or inflammatory cytokine. "Most of the damage happens due to this in IL-6 in patients. A Roche drug Tocilizumab works in this manner. Sepsivac or Mycobacterium w also stops the release of IL-6 which would control the multi-organ damage. A patient's innate immunity then has an opportunity to protect him," he explained. Mycobacterium w is not a SARS-CoV-2 (severe acute respiratory syndrome-coronavirus-2) virus-specific immunity. Further, in the Phase 3 trial, the plan is to give the drug to a group of 500 patients after they have recovered from the virus, so that they do not redevelop the disease in future.


54 employees test positive, ONGC halts ops at 2 rigs

SHINE JACOB
New Delhi, 22 June

State-run Oil and Natural Gas Corporation (ONGC) has halted operations at two drilling rigs in Western Coast, following the death of an employee and another 54 testing positive for coronavirus (Covid-19). The two rigs are in two of the most lucrative assets of the company — Mumbai High and Bassein. A company official said work stopped temporarily only at two rigs and the remaining 34 in the offshore were operational. He added there was no impact on the company's production. Mumbai High, also known as Bombay High, is an offshore oilfield located in the Arabian Sea, approximately 160 km west of the Mumbai coast. The field, discovered in 1974 and started production in 1976, is known primarily for its oil production. It also consists of two blocks — Mumbai High North and Mumbai High South. Mumbai High produces around 170,000 barrels of oil per day and 12 million metric standard cubic metres per day (mmscmd) of natural gas. On the other hand, Bassein field, also called the Vasai field, is located 80 km off the Mumbai coast and is considered one of the largest gas fields in India. The field was discovered in 1976 and put in production in 1988. Spread across 7,300 square kilometres in the Arabian Sea, it consists of South Bassein field, NBP (D-1) field, B-193 super sour field, Vasai East field and C-Series and Daman gas field. Bassein field produces 32 mmscmd of gas and 60,000 barrels of oil per day. ONGC claimed that works are going on following the standard operating procedure and its staff is properly informed about social distancing. Interestingly, ONGC employee bodies had reportedly alleged that the infection was spread



ON THE BSE



ing due to lack of proper guidelines. During the lockdown, its staff in Mumbai offshore fields were working continuously for five weeks. It was only after the lockdown restrictions were lifted did ONGC arrange for charter flights for their workers to reach Mumbai.

The company's overall production was hit badly by the lockdown due to the Covid 19 outbreak. In April, the company's natural gas production dropped by 15 per cent while its crude oil production dipped marginally by 0.5 per cent compared to the same month in 2019.

Overall, gas output of India for April also dropped 18.6 per cent to 2.16 billion cubic metres (bcm) against 2.65 bcm a year ago. Crude oil production also fell 6.35 per cent to 2.5 million tonnes (mt) in April.

The state-run major cut its capital expenditure (capex) by over 15 per cent or ₹5,000 crore for 2020-21. India's largest oil and gas producer had budgeted a capex of ₹32,502 crore for the financial year.

However, now it has been cut to around ₹27,500 crore. The company had also sought a price assurance of \$45 a barrel on crude oil.

Milkbasket gets \$5.5 million in fresh funding

Online grocery delivery start-up Milkbasket has raised \$5.5 million in a fresh funding round, led by Inflection Point Ventures, along with existing investors. The company will use the funding to grow its operations across India.

According to Milkbasket, its Gurugram, Noida and Bengaluru operations are already breaking even, with other cities on an accelerated track. With the latest round, the company has so far raised \$33 million.

SAMREEN AHMAD

Business Standard HYDERABAD EDITION

Printed and Published by Gopala Narayana on behalf of Business Standard Private Limited and printed at Enadu Press, Plot No : A/1, Block No : 3, Industrial Development Area, Uppal, 500 039, Rangareddy Dist. - Telangana and published at PTI Building, 11th Floor, A.C. Guards, Hyderabad-500 004

Editor : Shyamal Majumdar

RNI NO : AP ENG/2000/01017

Readers should write their feedback at feedback@bsmail.in Ph. 040-23375797 Fax : +91-40-23371863

For Subscription and Circulation enquiries please contact: Ms. Mani Singh **Head-Customer Relations** Business Standard Private Limited, H/4 & 1/3, Building H,Paragon Centre, Opp. Birla Centurion, PB.Marg, Worli, Mumbai - 400013 **E-mail:** subs_bs@bsmail.in "or sms, SUB BS to 57007"

DISCLAIMER News reports and feature articles in Business Standard seek to present an unbiased picture of developments in the markets, the corporate world and the government. Actual developments can turn out to be different owing to circumstances beyond Business Standard's control and knowledge. Business Standard does not take any responsibility for investment or business decisions taken by readers on the basis of reports and articles published in the newspaper. Readers are expected to form their own judgement. Business Standard does not associate itself with or stand by the contents of any of the advertisements accepted in good faith and published by it. Any claim related to the advertisements should be directed to the advertisers concerned. Unless explicitly stated otherwise, all rights reserved by M/s Business Standard Pvt. Ltd. Any printing, publication, reproduction, transmission or redissemination of the contents, in any form or by any means, is prohibited without the prior written consent of M/s Business Standard Pvt. Ltd. Any such prohibited and unauthorised act by any person/legal entity shall invite civil and criminal liabilities.

No Air Surcharge

ClearTax eyes foray into SME lending biz

DEBASIS MOHAPATRA
Bengaluru, 22 June

Online tax filing platform ClearTax is considering foraying into the lending business, with an aim of tapping the rising demand for loans among small and medium enterprises (SMEs) in the ongoing financial year.

The Bengaluru-headquartered firm plans to work as a marketplace for originating loans for SMEs through partnership with lenders such as banks and non-banking financial companies (NBFCs).

"Through our association with the SMEs, we have realised that the access to credit for SMEs is low.

Because of the Covid-19 pandemic, businesses are in need of credit. So, we have started a new division for this," said Archit Gupta, founder and CEO, ClearTax.

"We don't have our NBFC licence, so we will be partnering lenders for now."

Owing to Covid-induced slowdown, the fintech firm has seen drop in tax filing (GST) volume in the first 60

days of the lockdown period. "Things are coming back to normal as many businesses are reopening. Our business has reached 70 per cent of the pre-Covid level and we are hopeful that things will be normal by September," said Gupta.

The company, which has extended its work from home (WFH) option for its employees until September, said it had gained market share in comparison to its competitors in the tax filing space. "There has been a rapid growth from CA (chartered accountant) side (of the business), especially from areas like Gujarat and Maharashtra as these are the regions, which have been affected a lot. The number of CAs using this platform has also gone up," said Gupta.

He also said that many enterprises were migrating to Cloud because of the pandemic, leading to addition of new clients. In FY21, the company expects its growth to moderate marginally, though it is hopeful of still logging 75 per cent growth over the previous financial year. In FY20, the company expanded its revenue by 100 per cent. The company, which expects to reach break-even in the next 18 months, is also looking to increase its headcount in this financial year.

**Anjani Portland Cement Limited**
CIN: L26942MH1983PLC265166
Regd. Office: A-610, Kanakia Wall Street, 6th Floor, Andheri Kurla Road, Chakala Junction, Andheri (East), Mumbai-400093 Website: www.anjanacement.com
Tel No: 022-62396051 Email Id: secretariat@anjanacement.com

NOTICE
Pursuant to Regulation 29 read with Regulation 47 (1)(a) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Notice is hereby given that a meeting of the Board of Directors of the Company is scheduled to be held on Monday, June 29, 2020 inter alia to consider and approve the Audited Financial Results of the Company for the quarter and Year ended March 31, 2020 and to recommend a dividend, if any on the equity shares of the Company for the year ended March 31, 2020.
The said intimation will be available on the website of the Company at www.anjanacement.com and on the website of the BSE Limited at www.bseindia.com and NSE Limited at www.nseindia.com.
For Anjani Portland Cement Limited

Rohit Taparia
Company Secretary and Compliance Officer
(M.No: A35756)

**ALPHA GEO (INDIA) LIMITED**
CIN: L74210TG1987PLC007580
Regd. Office: 802, Babukhan Estate, Basheerbagh, Hyderabad – 500001
Corp. Office: Plot No.1, Sagor Society, Road No. 2, Banjara Hills, Hyderabad-500034
Tel: 040-23550502/ 503, Fax: 040-23550238, Email: cs@alphageoindia.com
Website: www.alphageoindia.com

NOTICE OF BOARD MEETING
Notice is hereby given that pursuant to Regulation 29 read with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, a meeting of the Board of Directors of the Company is scheduled to be held on **Monday, 29th June, 2020** inter alia to approve the Audited Financial Results of the Company for the quarter and year ended 31st March, 2020.
This Notice is also available on the website of the Company at <http://www.alphageoindia.com/>, BSE Ltd at <http://www.bseindia.com/> and National Stock Exchange of India Ltd at <http://www.nseindia.com/>.
For Alphageo (India) Limited
Deepta Dutta
Company Secretary

**AUROBINDO PHARMA LIMITED**
(CIN - L24239TG1986PLC015190)
Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad – 500038.
Tel No. +91 40 23736370 Fax No. +9140 23747340
E-mail: info@aurobindo.com Website: www.aurobindo.com

NOTICE
(For the kind attention of Shareholders of the Company)
Transfer of Equity Shares of the Company to Investors Education and Protection Fund
In terms of Section 124(6) of the Companies Act, 2013 (the "Act") read with Investors Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016 (the "Rules"), the Company is required to transfer the equity shares in respect of which dividend remains unpaid or unclaimed for seven consecutive years to Investors Education and Protection Fund (IEPF) Authority.
A list of such shareholders, who have not encashed their dividends for seven consecutive years from the final dividend declared by the Company in the year 2012-13 and whose shares are therefore liable for transfer to the IEPF account, is displayed on the website of the Company - www.aurobindo.com.
As per the said Rules, the Company has sent individual communication to the concerned shareholders whose shares are liable to be transferred to IEPF account for taking appropriate action by submitting requisite documents to claim the unclaimed dividend amount(s) by 31st August 2020. In the absence of receipt of a valid claim from the concerned shareholder, the Company would proceed to transfer the said unclaimed dividend and corresponding shares to IEPF account without further notice. All future benefits including dividends arising on such shares would also be transferred to IEPF.
Please note that no claim shall lie against the Company in respect of unclaimed dividend amounts and shares transferred to IEPF pursuant to the said rules. Shareholders can claim shares and dividend transferred to IEPF by complying due procedure given in the Rules, details of which are also available at www.iepf.gov.in.
For any information / clarification on the matter, the concerned shareholder may write to the Company at ig@aurobindo.com or contact the Company's Registrar and Share Transfer Agent - M/s KFin Technologies Pvt. Ltd., Selenium Tower-B, Plot 31-32, Gachibowli, Financial District, Nanakramguda, Hyderabad – 500032, Tel No.: 040-67162222, Fax No.: 040-233001153, email id: einward_ris@kfinetech.com.
For Aurobindo Pharma Limited
Sd/-
Place : Hyderabad B.Adi Reddy
Date : 18.06.2020 Company Secretary

THE ANDHRA SUGARS LIMITED
Regd. Office : Venkatarayapuram, TANUKU - 534 215
West Godavari District, Andhra Pradesh, India.
Phone : +91 -8819-224911 to 917.
E-mail : info.tnk@theandhrasugars.com, investors@theandhrasugars.com
Website: www.theandhrasugars.com
CIN: L15420AP1947PLC000326

NOTICE
Notice is hereby given that in compliance with the Provisions of Investor. Education and Protection Fund Authority (Accounting Audit, Transfer and Refund) Rules ("Rules"), 2016 and Section 124(6) of the Companies Act, 2013, which came into effect from 7th September, 2016, the Company is mandated to transfer all such shares in the name of Investor Education and Protection Fund (IEPF) Suspense Account in respect of which dividends has not been paid or claimed for seven consecutive years (2012-13 to 2018-19)
Notice is further given that in accordance with the provisions of the Rules, individual notices have already been sent to respective Shareholders at their latest available addresses in the Company inter alia providing the details of shares being transferred to IEPF suspense Account.
The concerned Shareholders are requested to claim the unpaid/unclaimed dividend amounts with full Bank account particulars as intimated individually failing which their shares shall be transferred to IEPF suspense account.
In case the concerned Shareholders wish to claim the shares after transfer to IEPF Suspense Account, a separate Application can be made to the IEPF Authority, in form IEPF-5, as prescribed under the Rules and the same is available at IEPF website i.e., www.iepf.gov.in.
For further information/request to claim the Unpaid/ Unclaimed Dividend(s), the concerned Shareholders may contact the Company at Regd. Office: Venkatarayapuram, TANUKU - 534215, Andhra Pradesh.
For THE ANDHRA SUGARS LIMITED
M. PALACHANDRA
Company Secretary
VENKATARAYAPURAM
22.06.2020.

**AIA ENGINEERING LIMITED**
Regd. Office.: Regd. Office.: 115, GVMM Estate, Odhav Road, Ahmedabad 382 410 CIN: L29259GJ1991PLC015182;
Ph. 079-22901078 Fax: 079-22901077; Website: www.aiaengineering.com, Email: ric@aiaengineering.com

Statement of Consolidated Audited Results for the Quarter and Year Ended 31st March, 2020

		(₹ in Lakhs)			
Sr. No.	Particulars	Consolidated			
		Quarter Ended		Year Ended	
		31/03/2020 Audited	31/03/2019 Audited	31/03/2020 Audited	31/03/2019 Audited
1	Total Income from Operations (Net)	85,693.42	88,799.22	298,087.75	306,949.99
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	18,574.66	19,025.02	71,872.43	69,440.01
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	18,574.66	19,025.02	71,872.43	69,440.01
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	14,242.22	15,589.32	59,032.01	51,143.77
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	16,325.26	16,925.76	58,638.31	50,490.47
6	Equity Share Capital			1,886.41	1,886.41
7	Reserves (excluding Revaluation Reserve) as per the Balance Sheet			368,242.23	349,484.40
8	Earnings Per Share (EPS) (of ₹ 2 each) (for continuing and discontinued operations) a. Basic b. Diluted	15.02 15.02	16.52 16.52	62.59 62.59	54.16 54.16

Notes:
1. The details of the following items on the Standalone basis:

		(₹ in Lakhs)			
Sr. No.	Particulars	Quarter Ended		Year Ended	
		31/03/2020 Audited	31/03/2019 Audited	31/03/2020 Audited	31/03/2019 Audited
	Total Income from Operations (Net)	71,192.40	74,006.23	258,762.44	283,758.50
	Profit Before Tax	43,184.40	13,511.42	95,741.03	60,191.41
	Profit After Tax	38,982.60	9,806.18	83,252.97	41,482.17
	Total Comprehensive income for the period (after tax)	39,323.95	9,705.81	83,515.58	41,577.33
2	The above is an extract of the detailed format of Financial Results for the Quarter / Year ended 31st March, 2020 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Financial Result for the Quarter / Year ended 31st March, 2020 are available on the Stock Exchange website (www.bseindia.com & www.nseindia.com) and Company's website (www.aiaengineering.com).				

**By Order of Board of Directors
For AIA Engineering Limited**
Sd/-
(Bhadresh K. Shah)
Managing Director
DIN:00058177

Place: Ahmedabad
Date: 22 June 2020

